tbuckley/cabot-search huggingface dataset:
Anakinra Injection Site Reaction on FDG PET/CT
Authors: Anne I.J. Arens, Dennis Vriens, Marijn Janssen, Anna Simon, Wim J.G. Oyen
Journal: Clinical Nuclear Medicine (2015)

Adult-onset Still's disease (AOSD) is a rare inflammatory disorder of unknown etiology, mainly characterized by fever, arthritis, skin rash, and raised ferritin concentration. FDG PET/CT scan of a 29-year-old woman with AOSD showed extensive lymphadenopathy, hypermetabolic splenomegaly, and increased bone marrow uptake consistent with AOSD activity. In addition, large dense lesions with high FDG uptake in the subcutaneous fat in the thighs corresponding to injection sites were seen. She had been treated with prednisone and daily subcutaneous injection of 100 mg anakinra before the scan indicating the subcutaneous lesions as injection site reactions to anakinra.
SP0167 How to Secure Cardiovascular Risk Factor Recording in Patients with Inflammatory Joint Diseases in Rheumatology Outpatient Clinics – A Norwegian Example
Authors: E. Ikdahl
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> The increased risk for cardiovascular (CV) disease (CVD) in patients with rheumatic joint diseases (RJD) has been well established. However, while programs for prevention of CVD have been developed for other chronic diseases associated with a high CV risk, including diabetes, familial hypercholesterolemia and chronic kidney disease; the CV risk in RJD patients is still poorly managed. The NOrwegain Collaboration on Atherosclerosis in patients with RJD (The NOCAR project) is a national effort to move the theoretical knowledge of increased CV risk in patients with RJD, into actual clinical management of CV risk factors and CVD. The NOCAR project involves 12 Norwegian rheumatology centres; from Tromsø in north, to Kristiansand in south. The aims of the project are to identify CV risk factors, calculate CV risk and ensure referral of RJD a patients at increased risk to further evaluation and initiation of adequate CV preventive measures. Accordingly, all centres have implemented an electronic journal program (GoTreatIt-rheuma [GTI]) featuring a designated CV module that facilitates the recording of CV risk factors. GTI also automatically calculates future risk of CVD by using the Systemic Coronary Risk Evaluation (SCORE) algorithm. In a busy rheumatology outpatient setting, the feasibility of a CV prevention project relies upon a non-time consuming, stream lined design. Thus, all visits in the NOCAR project is connected to annual visits in already ongoing rheumatology studies. Furthermore, the project focuses on three simple, key elements for CV risk evaluation: 1. Patient self-reported questionnaires on CV risk factors, medication and comorbidity (est. time 3-5 min) 2. Cholesterol values, measured as part of standard rheumatology blood works (est. time 2 min) 3. Brachial blood pressure, measured as part of the nurse consultation (est. time 4 min) Furthermore, nurses are instructed in delivering brief advice and brochures on healthy diet and smoking habits to all patients (est. time 3min). In a standardized letter, rheumatologists refer all patients with a calculated CV risk by SCORE ≥5% to a primary care physician or a cardiologist for the initiation of preventive measures. Finally, through biannual informational campaigns directed at rheumatology health personnel in the participating 12 centres, the NOCAR project has the potential to expand the daily clinical rheumatology perspective to also include CV comorbidity. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6269
A META–ANALYSIS OF MORTALITY AND MAJOR ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION VERSUS SURGICAL AORTIC VALVE REPLACEMENT FOR SEVERE AORTIC STENOSIS
Authors: Hemang B. Panchal, Saurabh Desai, Vijay Ramu
Journal: Journal of the American College of Cardiology (2013)
Transplantation of Cadaveric Kidneys from Patients with Hepatorenal Syndrome
Authors: Marcelo H. Koppel, Jack W. Coburn, Matlock M. Mims, Howard Goldstein, James D. Boyle, Milton E. Rubini
Journal: New England Journal of Medicine (1969)

Original Article from The New England Journal of Medicine — Transplantation of Cadaveric Kidneys from Patients with Hepatorenal Syndrome — Evidence for the Functional Nature of Renal Failure in Advanced Liver Disease
THU0542 Scores for Pain and Fatigue Explain Variation in Patient Global Status at Higher Significance Than Physical Function in Patients with Rheumatoid Arthritis (RA), Osteoarthritis (OA), Systemic Lupus Erythematosus (SLE) and Gout Seen in Usual Clinical Care
Authors: I. Castrejón, Y. Yazici, T. Pincus
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patient global estimate of clinical status (PATGL) is one of 3 patient self-report measures in the rheumatoid arthritis (RA) core data set, and often is the most sensitive measure to distinguish responses to active treatment from placebo in RA clinical trials. PATGL has also been found an informative measure in patients with rheumatic diseases other than RA. Pain has been found most explanatory of PATGL in RA, but the relative contribution of functional disability, pain and fatigue to explain PATGL in other rheumatic diseases remains poorly characterized. <h3>Objectives</h3> To analyze the significance of 3 self-report scores for functional disability, pain and fatigue to explain variation in PATGL in patients with all rheumatic diseases seen in a usual care rheumatology setting, and in subsets with RA, OA, SLE, gout, and all other diagnoses. <h3>Methods</h3> All patients seen at a rheumatology clinical setting complete a multidimensional heath assessment questionnaire (MDHAQ) at all visits, which includes physical function in 10 activities; visual analog scales (VAS) for pain, PATGL and fatigue; and demographic variables including age, formal education level and gender. The data are recorded in a longitudinal Access database, which was then transferred to STATA Version 11 for analyses. The last available visit of each patient with complete data for all variables was studied in a series of multivariate regressions to analyze the capacity of self-report scores for functional disability, pain and fatigue as independent variables to explain PATGL as the dependent variable in all patients and subgroups with RA, OA, SLE, gout, and other diagnoses. <h3>Results</h3> Overall, 2565 patients had complete data, including 517 with RA, 319 OA, 281 SLE, 98 gout and 1350 other diagnoses. Each of the 3 variables - functional disability, pain, and fatigue - independently explained patient global estimate, with highest significance for pain, intermediate for fatigue, and lowest (but significant) for functional disability. Pain was more dominant in RA, while fatigue was of greater relative significance in OA, SLE, gout and other diagnoses (Table). The R<sup>2</sup> in these 4 models ranged from 0.57–0.76, indicating robust explanation of variation in PATGL. <h3>Conclusions</h3> Pain, fatigue, and functional disability each were independently significant, in that order, to explain variation in PATGL; fatigue scores were less prominent in RA compared to OA, SLE, and gout. <h3>Disclosure of Interest</h3> None Declared
SP0066 What is the Target in Ra? Pursuing the Optimal Clinical Target
Authors: D. Porter
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> The concept of "Treat to Target" (T2T) has become embedded in the modern management of rheumatoid arthritis. Tight control of disease activity in the early stages of disease has been shown to result in improved rates of remission, physical function, and health-related quality of life, and to reduce radiographic progression. But which clinical tool should be used to measure disease activity, and what level of disease activity should be the target? Is it appropriate to aim for clinical remission (defined how?) in all patients? Or should the target be individualised depending on the patient9s social, demographic and medical circumstances? The studies of treatment strategy that underpin current "best practice" will be reviewed, in order to assess the evidence regarding: 1. which measure of disease activity should be utilised 2. what level of disease activity should be targeted 3. how effective T2T strategies are in terms of differing outcomes 4. is it possible or desirable to individualise the treatment target Rheumatologists learned from other disciplines of medicine, such as diabetology, as they developed T2T strategies of disease management. What more can we learn about the pursuit of tighter targets of disease control, from other disciplines? In particular, it is important to consider any disutility associated with ultra-tight management of disease activity, as well as the benefits. Is there evidence of any disutility associated with ultra-tight management of disease activity that needs to be taken into account? Illustrations from other diseases will be used to stimulate thought about the pros and cons of pursuing ultra-tight disease control. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6167
Abstract 3288: Isolation of anti-neoplastic drug candidates against metastatic breast, lungs and ovarian carcinoma cells.
Authors: Osman N. Ozes
Journal: Cancer Research (2013)

Abstract Cancer is a leading cause of death in man and women worl-wide. In recent years, wold-wide increase of obesity and diabetes, consumption of food additives and pollution are affecting quality of life and the incidense of all types of cancers are on the rise. Although new treatment regimens are also introduced into clinic war against cancer is still not won. Treatment of cancer with synthetic chemoterapics come with a unfavorable side effects which often ends therapy. Instead of investing in synthetic compounds, OZES BIOPHARMA is engaged in discovery of anti-neoplastic drug candidates from endemic plants of TURKEY. We have been extracting and analyzing organic compounds from variety of plants consumed as a food. Our search in past two years yielded very enchoraging results and we have discovered 6 novel compounds named OZS 1-6. Our compounds show significant levels of anti-tumor and anti-metastatic activities against human metastatic and non-metastatic breast cancer cells(MDA-231,MCF7), lung cancer cells (A549), Ovarian cancer cells (A2780) and its cisplatin resistant clone. Currently, we are idientifying the pathways inhibited or activated by our compounds. Citation Format: Osman N. Ozes. Isolation of anti-neoplastic drug candidates against metastatic breast, lungs and ovarian carcinoma cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3288. doi:10.1158/1538-7445.AM2013-3288
THU0116 Safety and efficacy of courses of rituximab in patients with rheumatoid arthritis - ritam study
Authors: N.S. Damjanov, D. Stefanovic, A. Dimic, T. Ilic, M. Lazarevic
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rituximab (RTX) is monoclonal antibody that selectively targets CD20+ B cells. The combination of RTX with MTX significantly improves disease symptoms in rheumathodi arthritis (RA) patients who have had an inadequate response to conventional DMARD therapy, and has been shown to improve quality of life in those patients. This is the only study that assessed efficacy and safety of RTX in daily practice in Serbia <h3>Objectives</h3> To determine the safety and efficacy of additional courses of RTX in patients with RA. <h3>Methods</h3> This is interim analysis of prospective noninterventional trial that enrolled 130 RA patients with inadequate response to previous biologic and/or synthetic DMARDs treated with RTX (age 50.37±11.59 years; 85.3% females and 14.7% males; disease duration 8.4±6.5 years). Patients were eligible for additional RTX courses (2 infusions of 1,000 mg given 2 weeks apart) if they exhibited disease reactivation measeured by DAS28. Efficacy was assessed by DAS28 (number of tender and swollen joints, VAS-GH, sedimentation) and the disability index of the Health Assessment Questionnaire at baseline and 24 weeks after first, second and third course. Safety was assessed by the number and severity of registered adverse events (AE). <h3>Results</h3> 114 patients received &gt;1 course of RTX (58 received 2 courses and 10 received 3 courses). Mean DAS28 scores decreased significantly from 6.41±0.97 at baseline to 4.91±1.65/4.33±1.23 and 3.86±1.43, 24 weeks after first/second/third RTX courses; p&lt;0.001. The proportions of patients with low disease activity (DAS28&lt;3.2) and in remission (DAS28&lt;2.6), increased following third RTX course (4.3% and 17.4%) compared to baseline. Proportion of patients with moderate disease activity (DAS28, 3.2-5.1) increased after 3 RTX course from 7.8% to 60.9%. Total HAD-DI score, before and after third RTX course was 2,25 (1,19) and 1,37 (1,78), respectively; p&lt;0,004. During the first/second/third courses AE were reported in 8/2/1 patients. No SAEs were reported. <h3>Conclusions</h3> During 3 courses of treatment, rituximab showed significant decrease of DAS28 and and increased quality of life measured by HAQ-DI questionnaire after each following rituximab course. <h3>Disclosure of Interest</h3> None Declared
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib
Authors: Robert J Motzer, Thomas E Hutson, Lauren McCann, Keith Deen, Toni K Choueiri
Journal: New England Journal of Medicine (2014)

Survival results are now mature for a noninferiority trial comparing pazopanib with sunitinib in renal-cell carcinoma. Median survival was 42.5 months with pazopanib and 43.6 months with sunitinib, a difference that wasnot significant.
Abstract 241: Tumor initiating cells and FZD8 play a major role in drugresistance and tumor progression in triple negative breast cancer.
Authors: Kaladhar B. Reddy, Shuping Yin, R. Bonfil Daniel, Sanjeev Banerjee, Fazlul Sarkar, Seema Sethi
Journal: Cancer Research (2013)

Abstract Triple-negative breast cancer (TNBC) is usually associated with poor outcome in part due to lack of benefit from targeted therapy. Previous studies have shown that neoadjuvant chemotherapy before surgery was effective in the minority of women with TNBC; in contrast, the majority who had a residual tumor after treatment had a relatively poor outcome. In order to identify the mechanism by which residual cancer cells survive chemotherapy, we performed gene expression profile using CRL2335 TNBC cell line before and after treatment with cisplatin plus TRAIL. We found a significant increase in the expression of FZD8, one of the Wnt receptors, and its downstream targets LEF1 and TCF in residual tumor cells after treatment with cisplatin plus TRAIL compared with untreated controls. Inhibition of FZD8 by siRNA in the presence of cisplatin plus TRAIL reduced β-catenin and survivin levels, and increased apoptosis compared to scrambled siRNA-treated cells. In vivo, data demonstrate that cisplatin plus TRAIL treatment, significantly reduces tumor volume in nod/SCID mice. However, we found that cisplatin plus TRAIL treatment predominantly eliminated non-tumor initiating cells (non-TICs), as demonstrated by whole-body fluorescent imaging of mice injected with mammosphere-forming cells stably transfected with DsRed. This led to TIC enrichment in residual tumors, as confirmed by immunostaining for TIC markers. Moreover, an increase in FZD8 expression was observed in residual tumors treated with cisplatin and TRAIL. Taken together, our findings suggest that FZD8-mediated Wnt-signaling may play a major role in mediating resistance to chemotherapy, making it a potential target to enhance chemotherapeutic efficacy in patients with TNBC. Citation Format: Kaladhar B. Reddy, Shuping Yin, R. Bonfil Daniel, Sanjeev Banerjee, Fazlul Sarkar, Seema Sethi. Tumor initiating cells and FZD8 play a major role in drugresistance and tumor progression in triple negative breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 241. doi:10.1158/1538-7445.AM2013-241
Abstract 499: High-level expression of the stem-cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis
Authors: Kyungeun Kim, Hyojin Ihm, Jae Y Ro, Sunghee Kang, Munjung Kang, Yong Mee Cho
Journal: Cancer Research (2011)

Abstract The cancer stem cell (CSC) model suggests that high levels of CSCs within a tumor are associated with poor prognosis. This study aims to investigate the expression of the stem cell marker CD133 in clear cell renal cell carcinoma (ccRCC) and its prognostic significance. The expression of CD133 was examined in 140 cases of ccRCC using immunohistochemistry. Ki-67 and Oct-4 were double immunostained with CD133 to evaluate the proliferative activity and the stemness of CD133-expressing cells, respectively. We observed CD133 expression in 45 cases (32.1%) and high levels of expression were associated with a macro-/microcystic pattern, no sarcomatoid changes, and non-metastatic disease. The Ki-67 labeling index tended to be lower in CD133-expressing ccRCCs compared with non-expressing tumors. CD133-expressing tumor cells rarely expressed Oct-4. CD133 was also highly expressed in renal intratubular neoplasia. This study demonstrated CD133 expression in pre-malignant and malignant renal diseases. We observed a high degree of CD133 expression in ccRCC with more differentiated morphology and non-metastatic disease, suggesting CD133 as a favorable prognostic marker. These results also imply that CD133 as a single marker may not be sufficient for CSC identification in ccRCC, and therefore, more specific CSC markers should be developed. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 499. doi:10.1158/1538-7445.AM2011-499
Abstract 1685: Inactivation of a transcriptional variant of MAP1LC3A gene in human cancers.
Authors: Jun Inoue, Hua Bai, Tatsuyuki Kawano, Johji Inazawa
Journal: Cancer Research (2013)

Abstract Autophagy functions to clear damaged or unfolded cellular components in the lysosomes as a survival pathway used by established cancers to sustain metabolism and tolerate stress. Autophagy, however, also suppress cancer initiation in liver and the accumulation of p62/SQSTM1 protein, a substrate for autophagic degradation, contributes to its tumorigenesis, suggesting that autophagy-related gene(s) may be actually inactivated in a part of human cancers at least. Recently, we have identified that a transcriptional variant of microtubule-associated protein 1 light chain 3A (LC3Av1), a member of human LC3 gene family, was frequently inactivated by aberrant DNA methylation in human cancers. Induction of wild-type LC3Av1 led to the decrease of p62 protein level, resulting in the inhibition of tumor growth, but not its mutant with the C-terminal glycine (lipidation site) changed to alanine. Thus, these results suggest that the impairment of autophagy through LC3Av1-silencing due to DNA methylation may be associated with tumorigenesis in various types of human cancer. Citation Format: Jun Inoue, Hua Bai, Tatsuyuki Kawano, Johji Inazawa. Inactivation of a transcriptional variant of MAP1LC3A gene in human cancers. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1685. doi:10.1158/1538-7445.AM2013-1685
PARADOXICAL LOW-FLOW, LOW-GRADIENT SEVERE AORTIC STENOSIS DESPITE PRESERVED EJECTION FRACTION IS ASSOCIATED WITH LOWER AORTIC VALVE RESISTANCE
Authors: Koichiro Takayama, Takahiro Ohara, Akira Funada, Hiroyuki Takahama, Makoto Amaki, Takuya Hasegawa, Yasuo Sugano, Hideaki Kanzaki, Teruo Noguchi, Kengo Kusano, Satoshi Yasuda, Hisao Ogawa, Toshihisa Anzai
Journal: Journal of the American College of Cardiology (2015)
Heart Disease in Pregnancy, by Ed Celia Oakley
Authors: K. Mahomed
Journal: BMJ (1997)

Ed Celia Oakley BMJ Publishing, £69.95, pp 442 ISBN 0 7279 1065 5

The personal experience of obstetricians and physicians with a special interest in heart disease in pregnancy is likely to be based on few cases. Because scientific evidence based on clinical trials is still scanty, the authors of this book—which is intended to help in the practical management of patients with cardiovascular problems in pregnancy—have used the wealth of experience from a specialist referral unit at Hammersmith Hospital.

The book is targeted at doctors working in countries such as Britain where congenital defects predominate. This is not …
Radioisotope Bone Scanning in Chronic Osseous Sarcoidosis
Authors: SALAH BENELHADJ, FRÉDÉRIC PATROIS, MICHÈLE DUET, BRUNO BÉROLATTI, OLIVIER MUNDLER
Journal: Clinical Nuclear Medicine (1996)

Sarcoidosis is rarely recognized as an osseous manifestations alone. Patients with osseous involvement usually have a chronic multivisceral form of the disease. The authors report a case of osseous sarcoidosis without other visceral involvement. A bone scan was requested to evaluate the extent of the bone involvement and explore buttocks pain.
THU0048 Role of Calcium/Calmodulin-Dependent Kinase Type IV in Podocyte Function in Lupus Nephritis
Authors: K. Ichinose, T. Ushigusa, T. Koga, G.C. Tsokos, A. Kawakami
Journal: Annals of the Rheumatic Diseases (2014)

A combined in vitro-in vivo renal function procedure has proved to be an important clinical tool in the nuclear medicine laboratory. This noninvasive test is relatively simple from the patient's standpoint. For the technologist, however, it involves scintigraphic imaging as well as a complex series of calculations including effective renal plasma flow, excretion rates, bladder retention, etc., all derived from a single injection of <sup>131</sup>I-orthoiodohippurate.
Case 31-2012
Authors: Phoebe H. Yager, Aneesh B. Singhal, Raul G. Nogueira
Journal: New England Journal of Medicine (2012)

An 18-year-old man suddenly became weak, with slurred speech. Dysarthria and ataxia were noted. Head CT was normal. The next day, he became unresponsive, with extensor posturing. A diagnostic procedure was performed.
Osseous metaplasia in a gastric adenomatous polyp
Authors: E. Zapata, A. Castiella, L. Zubiaurre, A. Agirre, J. Rodriguez
Journal: Endoscopy (2012)

Heterotopic bone is rarely found in the gastrointestinal tract. In the majority of reported cases, it was associated with malignant lesions [1] [2], Peutz–Jeghers syndrome [3], and more rarely with inflammatory colonic polyps [4]. On reviewing the literature, we found only two cases of metaplastic bone accompanying hyperplastic gastric mucosa [5] [6], and no case report of osseous metaplasia in gastric adenoma of the stomach.
Developing predictive assays: The phenotypic screening “rule of 3”
Authors: Fabien Vincent, Paula Loria, Marko Pregel, Robert Stanton, Linda Kitching, Karl Nocka, Regis Doyonnas, Claire Steppan, Adam Gilbert, Thomas Schroeter, Marie-Claire Peakman
Journal: Science Translational Medicine (2015)

Not all phenotypic assays are created equal; critically evaluating the disease relevance of the assay system, stimulus, and readout can help design the most predictive ones.